Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results
December 14, 2020 05:00 ET | Source: Amarin Corporation plc Amarin Corporation plc Bedminster, New Jersey, UNITED STATES
REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers
VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in outpatient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using VASCEPA loading dose
Amarin to Webcast Discussion of Presented Data Today, Monday, December 14, 2020 at 8:00 a.m., Eastern Standard Time
Drinking This Is Just As Dangerous As Drinking Soda, New Study Says
Drinking This Is Just As Dangerous As Drinking Soda, New Study Says
Study after study has noted that being a regular soda drinker is one of the worst things you can do to your body. After all, overconsumption of the sugary beverages over time can spur weight gain, increase your chances of getting type-2 diabetes, age your body prematurely, cause your skin to break out, lower your sperm count, affect your kidney health, rot your teeth, and hurt your heart. But if you think that you ll sidestep a lot of the bad side effects of drinking soda by switching to diet soda alternatives or other artificially sweetened beverages chiefly as it pertains to your heart we ve got bad news for you.
Diet soft drinks just as bad for you as regular ones claims study morefm.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morefm.co.nz Daily Mail and Mail on Sunday newspapers.
Ambulatory BP Monitoring Reliability Questioned for HTN Diagnosis medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Home / Top News / Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020
Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020
VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using VASCEPA loading dose
VASCEPA administration resulted in a significant 52% reduction of the total patient-reported symptom outcome prevalence score as compared to a 24% reduction in the usual care group